

Shiu-Lok Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9257930/publications.pdf>

Version: 2024-02-01

116
papers

5,121
citations

101384

36
h-index

102304

66
g-index

121
all docs

121
docs citations

121
times ranked

4355
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. <i>IScience</i> , 2022, 25, 104449.	1.9	16
2	Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge. <i>PLoS ONE</i> , 2021, 16, e0240495.	1.1	0
3	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. <i>PLoS ONE</i> , 2021, 16, e0257191.	1.1	19
4	In vivo Serial Passaging of Human-Simian Immunodeficiency Virus Clones Identifies Characteristics for Persistent Viral Replication. <i>Frontiers in Microbiology</i> , 2021, 12, 779460.	1.5	3
5	Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection. <i>Aids</i> , 2018, 32, 555-563.	1.0	17
6	Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. <i>Virology</i> , 2018, 514, 106-117.	1.1	29
7	Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation. <i>Nature Communications</i> , 2018, 9, 4438.	5.8	18
8	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	4.2	366
9	Intestinal damage precedes mucosal immune dysfunction in SIV infection. <i>Mucosal Immunology</i> , 2018, 11, 1429-1440.	2.7	46
10	Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy. <i>PLoS Pathogens</i> , 2018, 14, e1006956.	2.1	32
11	Extracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with $\hat{I}^{\pm 4}_{\hat{I}^2 7}$. <i>Journal of Virology</i> , 2017, 91, .	1.5	8
12	Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation. <i>JCI Insight</i> , 2017, 2, e91230.	2.3	24
13	A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host. <i>PLoS Pathogens</i> , 2017, 13, e1006358.	2.1	25
14	Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16007.	1.8	46
15	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. <i>Biochemistry</i> , 2016, 55, 2197-2213.	1.2	23
16	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. <i>Structure</i> , 2016, 24, 1346-1357.	1.6	35
17	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. <i>Journal of Virology</i> , 2016, 90, 9224-9236.	1.5	25
18	Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates. <i>Journal of Virology</i> , 2016, 90, 9471-9482.	1.5	43

#	ARTICLE	IF	CITATIONS
19	Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. <i>Journal of Virology</i> , 2016, 90, 8644-8660.	1.5	13
20	Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques. <i>Vaccine Journal</i> , 2016, 23, 204-212.	3.2	12
21	Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. <i>Journal of Virology</i> , 2016, 90, 829-841.	1.5	21
22	Assembly and characterization of gp160-nanodiscs: A new platform for biochemical characterization of HIV envelope spikes. <i>Journal of Virological Methods</i> , 2015, 226, 15-24.	1.0	7
23	Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation. <i>Aids</i> , 2015, 29, 1597-1606.	1.0	12
24	Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates. <i>Molecular Therapy</i> , 2015, 23, 943-951.	3.7	21
25	Multimodality vaccination against clade C SHIV: Partial protection against mucosal challenges with a heterologous tier 2 virus. <i>Vaccine</i> , 2014, 32, 6527-6536.	1.7	9
26	Dysregulation of multiple inflammatory molecules in lymph node and ileum of macaques during <sc>RT</sc>â€œ<sc>SHIV</sc> infection with or without antiretroviral therapy. <i>Journal of Medical Primatology</i> , 2014, 43, 298-309.	0.3	4
27	The Influence of HIV Envelope Glycosylation on Adaptive Immune Response. , 2014, , 59-83.		2
28	Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. <i>Protein Expression and Purification</i> , 2013, 90, 34-39.	0.6	11
29	Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120. <i>Journal of Virology</i> , 2013, 87, 10855-10873.	1.5	29
30	Robust suppression of envâ€œ<sc>SHIV</sc> viremia in <i><sc>M</sc>acaca nemestrina</i> by 3â€œdrug <sc>ART</sc> is independent of timing of initiation during chronic infection. <i>Journal of Medical Primatology</i> , 2013, 42, 237-246.	0.3	14
31	Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. <i>Blood</i> , 2013, 122, 179-187.	0.6	77
32	Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression. <i>PLoS ONE</i> , 2013, 8, e66973.	1.1	1
33	Simian Immunodeficiency Virus-Induced Alterations in Monocyte Production of Tumor Necrosis Factor Alpha Contribute to Reduced Immune Activation in Sooty Mangabeys. <i>Journal of Virology</i> , 2012, 86, 7605-7615.	1.5	13
34	Solution Structure, Conformational Dynamics, and CD4-Induced Activation in Full-Length, Glycosylated, Monomeric HIV gp120. <i>Journal of Virology</i> , 2012, 86, 8750-8764.	1.5	60
35	Isolation of Monoclonal Antibodies with Predetermined Conformational Epitope Specificity. <i>PLoS ONE</i> , 2012, 7, e38943.	1.1	12
36	Peripheral Blood Invariant Natural Killer T Cells of Pig-Tailed Macaques. <i>PLoS ONE</i> , 2012, 7, e48166.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Dynamics of Envelope Evolution in Clade C SHIV-Infected Pig-Tailed Macaques during Disease Progression Analyzed by Ultra-Deep Pyrosequencing. <i>PLoS ONE</i> , 2012, 7, e32827.	1.1	3
38	Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: Efficacy against repeated mucosal R5 clade C SHIV challenges. <i>Vaccine</i> , 2011, 29, 5611-5622.	1.7	35
39	Vif Substitution Enables Persistent Infection of Pig-Tailed Macaques by Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2011, 85, 3767-3779.	1.5	41
40	Genetic Diversity of Simian Immunodeficiency Virus Encoding HIV-1 Reverse Transcriptase Persists in Macaques despite Antiretroviral Therapy. <i>Journal of Virology</i> , 2011, 85, 1067-1076.	1.5	39
41	Variable Prevalence and Functional Diversity of the Antiretroviral Restriction Factor TRIMCyp in <i>Macaca fascicularis</i> . <i>Journal of Virology</i> , 2011, 85, 9956-9963.	1.5	38
42	Vaccination against Heterologous R5 Clade C SHIV: Prevention of Infection and Correlates of Protection. <i>PLoS ONE</i> , 2011, 6, e22010.	1.1	22
43	Comparative Immunogenicity of Subtype A Human Immunodeficiency Virus Type 1 Envelope Exhibiting Differential Exposure of Conserved Neutralization Epitopes. <i>Journal of Virology</i> , 2010, 84, 2573-2584.	1.5	21
44	Evolution of the Antiretroviral Restriction Factor TRIMCyp in Old World Primates. <i>PLoS ONE</i> , 2010, 5, e14019.	1.1	22
45	Pathogenic infection of <i>Macaca nemestrina</i> with a CCR5-tropic subtype-C simian-human immunodeficiency virus. <i>Retrovirology</i> , 2009, 6, 65.	0.9	23
46	Differential pathogenicity of SHIV _{SF162 P4} infection in pig-tailed and rhesus macaques. <i>Journal of Medical Primatology</i> , 2008, 37, 13-23.	0.3	28
47	TRIMCyp expression in Old World primates <i>Macaca nemestrina</i> and <i>Macaca fascicularis</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3569-3574.	3.3	167
48	Characterization of Neutralizing Antibody Responses Elicited by Clade A Envelope Immunogens Derived from Early Transmitted Viruses. <i>Journal of Virology</i> , 2008, 82, 5912-5921.	1.5	19
49	The Use of Nonhuman Primate Models in HIV Vaccine Development. <i>PLoS Medicine</i> , 2008, 5, e173.	3.9	87
50	Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. <i>Journal of Virology</i> , 2008, 82, 638-651.	1.5	154
51	Inducing Cross-Clade Neutralizing Antibodies against HIV-1 by Immunofocusing. <i>PLoS ONE</i> , 2008, 3, e3937.	1.1	25
52	Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy. <i>Journal of Virology</i> , 2007, 81, 12145-12155.	1.5	51
53	Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. <i>Aids</i> , 2007, 21, 1841-1848.	1.0	22
54	Dendritic Cell-Based Vaccine Strategy against Human Immunodeficiency Virus Clade C: Skewing The Immune Response Toward A Helper T Cell Type 2 Profile. <i>Viral Immunology</i> , 2007, 20, 160-169.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Novel TRIM5 Isoforms Expressed by <i>Macaca nemestrina</i> . Journal of Virology, 2007, 81, 12210-12217.	1.5	59
56	Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3. Journal of Virology, 2007, 81, 822-834.	1.5	32
57	Prospects of HIV Env Modification as an Approach to HIV Vaccine Design. Current HIV Research, 2007, 5, 507-513.	0.2	42
58	Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge. Journal of Medical Primatology, 2007, 36, 254-265.	0.3	25
59	DNA prime/protein boost immunization against HIV clade C: Safety and immunogenicity in mice. Vaccine, 2006, 24, 2324-2332.	1.7	19
60	Response to. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 394.	0.9	44
61	Transduction of Macaque Hematopoietic Repopulating Cells with Lenti and Foamy Retroviral Vectors with MGMT Selection Cassettes To Evaluate AIDS Gene Therapy Strategies.. Blood, 2006, 108, 3273-3273.	0.6	0
62	Non-Human Primate Models for AIDS Vaccine Research. Current Drug Targets Infectious Disorders, 2005, 5, 193-201.	2.1	77
63	Rapid Viral Escape at an Immunodominant Simian-Human Immunodeficiency Virus Cytotoxic T-Lymphocyte Epitope Exact a Dramatic Fitness Cost. Journal of Virology, 2005, 79, 5721-5731.	1.5	164
64	A Non-Human Primate Model To Study Anti-HIV Gene Therapy Strategies.. Blood, 2005, 106, 3046-3046.	0.6	0
65	Passive Immunotherapy in Simian Immunodeficiency Virus-Infected Macaques Accelerates the Development of Neutralizing Antibodies. Journal of Virology, 2004, 78, 5983-5995.	1.5	99
66	Protective Immunity to SIV Challenge Elicited by Vaccination of Macaques with Multigenic DNA Vaccines Producing Virus-Like Particles. AIDS Research and Human Retroviruses, 2004, 20, 425-434.	0.5	24
67	Perinatal transmission of SHIV-SF162P3 in <i>Macaca nemestrina</i> . Journal of Medical Primatology, 2004, 33, 243-250.	0.3	19
68	Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. Virology, 2004, 323, 208-219.	1.1	12
69	HIV in central nervous system and behavioral development. Aids, 2004, 18, 1363-1370.	1.0	11
70	Evidence for immune-mediated reduction of viral replication in <i>Macaca nemestrina</i> mucosally immunized with inactivated SHIV89.6. Virology, 2003, 308, 178-190.	1.1	3
71	Derivation and characterization of a highly pathogenic isolate of human immunodeficiency virus type 2 that causes rapid CD4+ cell depletion in <i>Macaca nemestrina</i> . Journal of Medical Primatology, 2003, 29, 114-126.	0.3	27
72	Multigene DNA prime-boost vaccines for SHIV89.6P. Journal of Medical Primatology, 2003, 32, 218-228.	0.3	15

#	ARTICLE	IF	CITATIONS
73	Lipidâ€Drug Association Enhanced HIV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2287-Infected Macaques. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 387-397.	0.9	79
74	Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2002, 76, 2606-2616.	1.5	133
75	Short Communication:N-Linked Glycosylation in the V3 Region of HIV Type 1 Surface Antigen Modulates Coreceptor Usage in Viral Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1473-1479.	0.5	50
76	Conserved CXCR4 usage and enhanced replicative capacity of HIV-2/287, an isolate highly pathogenic in <i>Macaca nemestrina</i> . <i>Aids</i> , 2001, 15, 2349-2357.	1.0	8
77	Evidence for Early Local Viral Replication and Local Production of Antiviral Immunity upon Mucosal Simian-Human Immunodeficiency Virus SHIV 89.6 Infection in <i>Macaca nemestrina</i> . <i>Journal of Virology</i> , 2001, 75, 8589-8596.	1.5	20
78	Rapid Shift from Virally Infected Cells to Germinal Center-Retained Virus after HIV-2 Infection of Macaques. <i>American Journal of Pathology</i> , 2000, 156, 1197-1207.	1.9	3
79	Immunization against SIMne in macaques using multigenic DNA vaccines. <i>Journal of Medical Primatology</i> , 1999, 28, 206-213.	0.3	19
80	Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. <i>Nature Medicine</i> , 1999, 5, 526-534.	15.2	370
81	Thrombotic Microangiopathy in the HIV-2-Infected Macaque. <i>American Journal of Pathology</i> , 1999, 155, 649-661.	1.9	29
82	Limited Breadth of the Protective Immunity Elicited by Simian Immunodeficiency Virus SIMne gp160 Vaccines in a Combination Immunization Regimen. <i>Journal of Virology</i> , 1999, 73, 618-630.	1.5	53
83	Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIMne in Protection against Homologous Cloned and Unclassified Virus Challenge in Macaques. <i>Journal of Virology</i> , 1999, 73, 8201-8215.	1.5	63
84	Protection of Macaques against Intrarectal Infection by a Combination Immunization Regimen with Recombinant Simian Immunodeficiency Virus SIMne gp160 Vaccines. <i>Journal of Virology</i> , 1999, 73, 3134-3146.	1.5	49
85	A Minimally Replicative HIV-2 Live-Virus Vaccine Protects <i>M. nemestrina</i> from Disease after HIV-2287 Challenge. <i>Virology</i> , 1998, 242, 150-160.	1.1	37
86	Genetic Variation in a Human Immunodeficiency Virus Type 2 Live-Virus<i>Macaca nemestrina</i> Vaccine Model. <i>Journal of Virology</i> , 1998, 72, 7871-7884.	1.5	8
87	Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting. <i>Journal of Virology</i> , 1998, 72, 9092-9100.	1.5	110
88	Early Postinfection Antiviral Treatment Reduces Viral Load and Prevents CD4⁺ Cell Decline in HIV Type 2-Infected Macaques. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 1375-1381.	0.5	58
89	Conservation of DNA Sequence in the Predicted Major Late Promoter Regions of Selected Mastadenoviruses. <i>Virology</i> , 1996, 220, 390-401.	1.1	25
90	Development of a chronically catheterized maternalâ€fetal macaque model to study in utero motherâ€toâ€fetus HIV transmission: A preliminary report. <i>Journal of Medical Primatology</i> , 1996, 25, 218-224.	0.3	14

#	ARTICLE	IF	CITATIONS
91	Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. <i>Immunology Letters</i> , 1996, 51, 107-114.	1.1	144
92	Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection. <i>Immunology Letters</i> , 1996, 51, 115-119.	1.1	17
93	Recombinant Subunit Vaccines against Primate Lentiviruses. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 451-453.	0.5	10
94	Influence of N-Linked Glycans in V4-V5 Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp160 on Induction of a Virus-Neutralizing Humoral Response. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 12, 213-220.	0.3	73
95	Studies of Complement-Activating Antibodies in the SIV/Macaque Model of Acute Primary Infection and Vaccine Protection. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 963-970.	0.5	28
96	Interface between Animal Models and Clinical Phase I Trials Workshop: Conference Summary. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1305-1306.	0.5	2
97	Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 551-560.	0.5	18
98	Terpestatin, a new syncytium formation inhibitor from <i>Arthrinium</i> sp.. <i>Journal of Antibiotics</i> , 1993, 46, 367-373.	1.0	72
99	Protection of vaccinia-primed macaques against SIV mne infection by combination immunization with recombinant vaccinia virus and SIV mne gp160. <i>Journal of Medical Primatology</i> , 1993, 22, 92-99.	0.3	25
100	Immune Responses to SIV Envelope Glycoproteins Protect Macaques from Homologous SIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1489-1494.	0.5	21
101	Evaluation of gp160 Vaccines in the hu-PBL-SCID Mouse Model. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1387-1387.	0.5	17
102	Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells. <i>Virology</i> , 1992, 186, 313-317.	1.1	63
103	Evaluation of protective efficacy of recombinant subunit vaccines against simian immunodeficiency virus infection of macaques. <i>Journal of Medical Primatology</i> , 1992, 21, 119-125.	0.3	15
104	HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. <i>Virology</i> , 1991, 183, 487-495.	1.1	38
105	Cross-Neutralizing Antibodies in Rabbits Immunized with HIV-1 gp160 Purified from Simian Cells Infected with a Recombinant Vaccinia Virus. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 791-798.	0.5	36
106	Neutralizing Antibodies Against HIV-1 BRU and SF2 Isolates Generated in Mice Immunized with Recombinant Vaccinia Virus Expressing HIV-1 (BRU) Envelope Glycoproteins and Boosted with Homologous gp160. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 615-620.	0.5	60
107	Tumorigenic poxviruses: Characterization of the expression of an epidermal growth factor related gene in Shope fibroma virus. <i>Virology</i> , 1990, 179, 926-930.	1.1	17
108	Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. <i>Virology</i> , 1990, 179, 321-329.	1.1	74

#	ARTICLE	IF	CITATIONS
109	Nucleotide and deduced amino acid sequence of the bovine adenovirus type 3 proteinase. <i>Nucleic Acids Research</i> , 1990, 18, 5568-5568.	6.5	8
110	Nucleotide and deduced amino acid sequence of the bovine adenovirus type 7 proteinase. <i>Nucleic Acids Research</i> , 1990, 18, 5567-5567.	6.5	12
111	Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. <i>Nature</i> , 1987, 328, 721-723.	13.7	215
112	Synthesis of an active hybrid growth factor (GF) in bacteria: transforming GF- $\hat{\iota}$ /vaccinia GF fusion protein. <i>Gene</i> , 1987, 60, 175-182.	1.0	15
113	Expression of AIDS virus envelope gene in recombinant vaccinia viruses. <i>Nature</i> , 1986, 320, 537-540.	13.7	206
114	T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. <i>Nature</i> , 1986, 323, 344-346.	13.7	99
115	Translational control of SV40 T antigen expressed from the adenovirus late promoter. <i>Cell</i> , 1983, 33, 455-464.	13.5	87
116	Regulation of integration by coliphage $\hat{\iota}$: Activation of int transcription by the cII and cIII proteins. <i>Virology</i> , 1979, 92, 542-556.	1.1	36